98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10895-024-03583-2 | DOI Listing |
Cell Mol Gastroenterol Hepatol
September 2025
Department of Pathology & Laboratory Medicine, Emory University, Atlanta, USA. Electronic address:
Background & Aims: Formylated peptide receptors 1 and 2 (Fpr1/2 or FPRs) are G-protein-coupled pattern recognition receptors that bind bacterial formylated peptides. The role of FPRs in enteric nervous system (ENS) development and gastrointestinal (GI) motility is unknown.
Methods: We generated mice with germline, epithelial-, and neural crest-specific deletion of the Fpr1/2 locus and assessed ENS structure and GI motility.
Org Biomol Chem
August 2025
Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.
Correction for 'NHC-catalysed synthesis of hydroxy methylene-bridged formyl-di-xylofuranose: access to tetrakis and spiro tricyclic xylofuranose' by Norein Sakander , , 2025, , 3824-3829, https://doi.org/10.1039/D5OB00259A.
View Article and Find Full Text PDFAcc Chem Res
June 2025
Beijing National Laboratory for Molecular Sciences (BNLMS), CAS Key Laboratory of Molecular Recognition and Function, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
ConspectusRNA epigenetics has rapidly emerged as a key frontier in chemical biology, revealing that modifications to RNA bases and riboses can fine-tune essential cellular processes such as gene expression, translation, and metabolic homeostasis. Traditionally, researchers have relied on manipulating the "writers," "erasers," and "readers" of RNA modifications─, protein cofactors─to alter and study these marks. Those enzyme-centric strategies, including small molecule inhibitors and CRISPR/Cas-based genetic perturbations, have been highly effective and are advancing in clinical applications.
View Article and Find Full Text PDFActa Pharmacol Sin
July 2025
Department of Clinical Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, 201102, China.
Current treatments of inflammatory bowel disease (IBD) largely depend on anti-inflammatory and immunosuppressive strategies with unacceptable efficacy and adverse events. Resolution or repair agents to treat IBD are not available but potential targets like formyl peptide receptor 2 (FPR2/ALX) may fill the gap. In this study we evaluated the therapeutic effects of two small molecule FPR2/ALX modulators (agonist Quin-C1 and antagonist Quin-C7) against IBD.
View Article and Find Full Text PDF